Heathcare Treasure

Hereditary Transthyretin Amyloidosis (hATTR) is a rare, progressive, and life-threatening genetic disorder caused by mutations in the transthyretin (TTR) gene. This leads to the misfolding of TTR proteins, which accumulate as amyloid fibrils in various organs and tissues, disrupting their normal function. The most commonly affected organs include the peripheral nerves, heart, and gastrointestinal tract, leading to symptoms like peripheral neuropathy, cardiomyopathy, and gastrointestinal disturbances. Hereditary Transthyretin Amyloidosis Market Insights The global hATTR market has been experiencing significant growth due to increasing awareness, advances in diagnostic techniques, and the development of novel therapeutics. In recent years, several drugs have been approved that offer symptomatic relief and, in some cases, slow disease progression.  Key Hereditary Transthyretin Amyloidosis Companies In The Market Landscape: Several hATTR companies such as Pfizer, Alnylam Pharmaceuticals,